APO Research
Talk to an analyst

APO RESEARCH · REPORT

Trivalent Inactivated Influenza Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Trivalent Inactivated Influenza Vaccine Industry Research Report 2026

29 December 2025120 pages

Choose your research edition.

Industry ResearchTrivalent Inactivated Influenza Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Trivalent Inactivated Influenza Vaccine Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Trivalent Inactivated Influenza Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Trivalent Inactivated Influenza Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Trivalent Inactivated Influenza Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Trivalent Inactivated Influenza Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Trivalent Inactivated Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Trivalent Inactivated Influenza Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Trivalent Inactivated Influenza Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Trivalent Inactivated Influenza Vaccine include CSL Limited, Sanofi S.A, Serum Institute of India, AstraZeneca, GlaxoSmithKline, Pfizer, Merck, Novartis and Abbott, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Trivalent Inactivated Influenza Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Trivalent Inactivated Influenza Vaccine Market by Company

CSL Limited

Sanofi S.A

Serum Institute of India

AstraZeneca

GlaxoSmithKline

Pfizer

Merck

Novartis

Abbott

Trivalent Inactivated Influenza Vaccine Segment by Type

Intradermal Injection

Intramuscular Injection

Nasal Spray

Trivalent Inactivated Influenza Vaccine Segment by Application

Public Health Agency

Hospital

Clinic

Others

Trivalent Inactivated Influenza Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Trivalent Inactivated Influenza Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Trivalent Inactivated Influenza Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Trivalent Inactivated Influenza Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Trivalent Inactivated Influenza Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Trivalent Inactivated Influenza Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Trivalent Inactivated Influenza Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Trivalent Inactivated Influenza Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Trivalent Inactivated Influenza Vaccine Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Trivalent Inactivated Influenza Vaccine Revenue of Manufacturers (2021-2026) Table 9. Global Trivalent Inactivated Influenza Vaccine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Trivalent Inactivated Influenza Vaccine Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Trivalent Inactivated Influenza Vaccine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Trivalent Inactivated Influenza Vaccine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Trivalent Inactivated Influenza Vaccine, Product Type & Application Table 14. Global Trivalent Inactivated Influenza Vaccine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Trivalent Inactivated Influenza Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. CSL Limited Company Information Table 19. CSL Limited Business Overview Table 20. CSL Limited Trivalent Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. CSL Limited Trivalent Inactivated Influenza Vaccine Product Portfolio Table 22. CSL Limited Recent Developments Table 23. Sanofi S.A Company Information Table 24. Sanofi S.A Business Overview Table 25. Sanofi S.A Trivalent Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sanofi S.A Trivalent Inactivated Influenza Vaccine Product Portfolio Table 27. Sanofi S.A Recent Developments Table 28. Serum Institute of India Company Information Table 29. Serum Institute of India Business Overview Table 30. Serum Institute of India Trivalent Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Serum Institute of India Trivalent Inactivated Influenza Vaccine Product Portfolio Table 32. Serum Institute of India Recent Developments Table 33. AstraZeneca Company Information Table 34. AstraZeneca Business Overview Table 35. AstraZeneca Trivalent Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. AstraZeneca Trivalent Inactivated Influenza Vaccine Product Portfolio Table 37. AstraZeneca Recent Developments Table 38. GlaxoSmithKline Company Information Table 39. GlaxoSmithKline Business Overview Table 40. GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product Portfolio Table 42. GlaxoSmithKline Recent Developments Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer Trivalent Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Pfizer Trivalent Inactivated Influenza Vaccine Product Portfolio Table 47. Pfizer Recent Developments Table 48. Merck Company Information Table 49. Merck Business Overview Table 50. Merck Trivalent Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Merck Trivalent Inactivated Influenza Vaccine Product Portfolio Table 52. Merck Recent Developments Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Trivalent Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Novartis Trivalent Inactivated Influenza Vaccine Product Portfolio Table 57. Novartis Recent Developments Table 58. Abbott Company Information Table 59. Abbott Business Overview Table 60. Abbott Trivalent Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Abbott Trivalent Inactivated Influenza Vaccine Product Portfolio Table 62. Abbott Recent Developments Table 63. Global Trivalent Inactivated Influenza Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 64. Global Trivalent Inactivated Influenza Vaccine Sales by Region (2021-2026) & (K Units) Table 65. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Region (2021-2026) Table 66. Global Trivalent Inactivated Influenza Vaccine Sales by Region (2027-2032) & (K Units) Table 67. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Region (2027-2032) Table 68. Global Trivalent Inactivated Influenza Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 69. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Region (2021-2026) Table 70. Global Trivalent Inactivated Influenza Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 71. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Region (2027-2032) Table 72. North America Trivalent Inactivated Influenza Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. North America Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2026) & (K Units) Table 74. North America Trivalent Inactivated Influenza Vaccine Sales by Country (2027-2032) & (K Units) Table 75. North America Trivalent Inactivated Influenza Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 76. North America Trivalent Inactivated Influenza Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 77. Europe Trivalent Inactivated Influenza Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2026) & (K Units) Table 79. Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2027-2032) & (K Units) Table 80. Europe Trivalent Inactivated Influenza Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 81. Europe Trivalent Inactivated Influenza Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 82. Asia Pacific Trivalent Inactivated Influenza Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Asia Pacific Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2026) & (K Units) Table 84. Asia Pacific Trivalent Inactivated Influenza Vaccine Sales by Country (2027-2032) & (K Units) Table 85. Asia Pacific Trivalent Inactivated Influenza Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 86. Asia Pacific Trivalent Inactivated Influenza Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 87. South America Trivalent Inactivated Influenza Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. South America Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2026) & (K Units) Table 89. South America Trivalent Inactivated Influenza Vaccine Sales by Country (2027-2032) & (K Units) Table 90. South America Trivalent Inactivated Influenza Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 91. South America Trivalent Inactivated Influenza Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 92. Middle East and Africa Trivalent Inactivated Influenza Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2026) & (K Units) Table 94. Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2027-2032) & (K Units) Table 95. Middle East and Africa Trivalent Inactivated Influenza Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 96. Middle East and Africa Trivalent Inactivated Influenza Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 97. Global Trivalent Inactivated Influenza Vaccine Sales by Type (2021-2026) & (K Units) Table 98. Global Trivalent Inactivated Influenza Vaccine Sales by Type (2027-2032) & (K Units) Table 99. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2021-2026) Table 100. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2027-2032) Table 101. Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 102. Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 103. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2021-2026) Table 104. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2027-2032) Table 105. Global Trivalent Inactivated Influenza Vaccine Price by Type (2021-2026) & (US$/Unit) Table 106. Global Trivalent Inactivated Influenza Vaccine Price by Type (2027-2032) & (US$/Unit) Table 107. Global Trivalent Inactivated Influenza Vaccine Sales by Application (2021-2026) & (K Units) Table 108. Global Trivalent Inactivated Influenza Vaccine Sales by Application (2027-2032) & (K Units) Table 109. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2021-2026) Table 110. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2027-2032) Table 111. Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 112. Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 113. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2021-2026) Table 114. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2027-2032) Table 115. Global Trivalent Inactivated Influenza Vaccine Price by Application (2021-2026) & (US$/Unit) Table 116. Global Trivalent Inactivated Influenza Vaccine Price by Application (2027-2032) & (US$/Unit) Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Trivalent Inactivated Influenza Vaccine Distributors List Table 120. Trivalent Inactivated Influenza Vaccine Customers List Table 121. Trivalent Inactivated Influenza Vaccine Industry Trends Table 122. Trivalent Inactivated Influenza Vaccine Industry Drivers Table 123. Trivalent Inactivated Influenza Vaccine Industry Restraints Table 124. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Trivalent Inactivated Influenza Vaccine Product Image Figure 5. Global Trivalent Inactivated Influenza Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Trivalent Inactivated Influenza Vaccine Market Size (2021-2032) & (US$ Million) Figure 7. Global Trivalent Inactivated Influenza Vaccine Sales (2021-2032) & (K Units) Figure 8. Global Trivalent Inactivated Influenza Vaccine Average Price (US$/Unit) & (2021-2032) Figure 9. Intradermal Injection Product Image Figure 10. Intramuscular Injection Product Image Figure 11. Nasal Spray Product Image Figure 12. Public Health Agency Product Image Figure 13. Hospital Product Image Figure 14. Clinic Product Image Figure 15. Others Product Image Figure 16. Global Trivalent Inactivated Influenza Vaccine Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Trivalent Inactivated Influenza Vaccine, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Trivalent Inactivated Influenza Vaccine Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Trivalent Inactivated Influenza Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Trivalent Inactivated Influenza Vaccine Sales by Region in 2025 Figure 22. Global Trivalent Inactivated Influenza Vaccine Revenue by Region in 2025 Figure 23. North America Trivalent Inactivated Influenza Vaccine Market Size by Country in 2025 Figure 24. North America Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2021-2032) Figure 25. North America Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2021-2032) Figure 26. United States Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Trivalent Inactivated Influenza Vaccine Market Size by Country in 2025 Figure 29. Europe Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2021-2032) Figure 30. Europe Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2021-2032) Figure 31. Germany Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Asia Pacific Trivalent Inactivated Influenza Vaccine Market Size by Country in 2025 Figure 37. Asia Pacific Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2021-2032) Figure 38. Asia Pacific Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2021-2032) Figure 39. China Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Japan Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. South Korea Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. India Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Australia Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. China Taiwan Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South America Trivalent Inactivated Influenza Vaccine Market Size by Country in 2025 Figure 48. South America Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2021-2032) Figure 49. South America Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2021-2032) Figure 50. Mexico Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Brazil Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Argentina Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Middle East and Africa Trivalent Inactivated Influenza Vaccine Market Size by Country in 2025 Figure 54. Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2021-2032) Figure 55. Middle East and Africa Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2021-2032) Figure 56. Turkey Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Saudi Arabia Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. UAE Trivalent Inactivated Influenza Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2021-2032) Figure 60. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2021-2032) Figure 61. Global Trivalent Inactivated Influenza Vaccine Price (US$/Unit) by Type (2021-2032) Figure 62. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2021-2032) Figure 63. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2021-2032) Figure 64. Global Trivalent Inactivated Influenza Vaccine Price (US$/Unit) by Application (2021-2032) Figure 65. Trivalent Inactivated Influenza Vaccine Value Chain Figure 66. Trivalent Inactivated Influenza Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Trivalent Inactivated Influenza Vaccine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Intradermal Injection
  • Intramuscular Injection
  • Nasal Spray
Applications
  • Public Health Agency
  • Hospital
  • Clinic
  • Others
Companies covered
  • CSL Limited
  • Sanofi S.A
  • Serum Institute of India
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Merck
  • Novartis
  • Abbott

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Trivalent Inactivated Influenza Vaccine Market Size (2021-2032)
  4. 2.2.2 Global Trivalent Inactivated Influenza Vaccine Sales (2021-2032)
  5. 2.2.3 Global Trivalent Inactivated Influenza Vaccine Market Average Price (2021-2032)
  6. 2.3 Trivalent Inactivated Influenza Vaccine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Intradermal Injection
  9. 2.3.3 Intramuscular Injection
  10. 2.3.4 Nasal Spray
  11. 2.4 Trivalent Inactivated Influenza Vaccine by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Public Health Agency
  14. 2.4.3 Hospital
  15. 2.4.4 Clinic
  16. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Trivalent Inactivated Influenza Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Trivalent Inactivated Influenza Vaccine Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Trivalent Inactivated Influenza Vaccine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Trivalent Inactivated Influenza Vaccine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Trivalent Inactivated Influenza Vaccine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Trivalent Inactivated Influenza Vaccine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Trivalent Inactivated Influenza Vaccine, Product Type & Application
  8. 3.8 Global Manufacturers of Trivalent Inactivated Influenza Vaccine, Established Date
  9. 3.9 Global Trivalent Inactivated Influenza Vaccine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 CSL Limited
  2. 4.1.1 CSL Limited Company Information
  3. 4.1.2 CSL Limited Business Overview
  4. 4.1.3 CSL Limited Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 CSL Limited Trivalent Inactivated Influenza Vaccine Product Portfolio
  6. 4.1.5 CSL Limited Recent Developments
  7. 4.2 Sanofi S.A
  8. 4.2.1 Sanofi S.A Company Information
  9. 4.2.2 Sanofi S.A Business Overview
  10. 4.2.3 Sanofi S.A Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi S.A Trivalent Inactivated Influenza Vaccine Product Portfolio
  12. 4.2.5 Sanofi S.A Recent Developments
  13. 4.3 Serum Institute of India
  14. 4.3.1 Serum Institute of India Company Information
  15. 4.3.2 Serum Institute of India Business Overview
  16. 4.3.3 Serum Institute of India Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Serum Institute of India Trivalent Inactivated Influenza Vaccine Product Portfolio
  18. 4.3.5 Serum Institute of India Recent Developments
  19. 4.4 AstraZeneca
  20. 4.4.1 AstraZeneca Company Information
  21. 4.4.2 AstraZeneca Business Overview
  22. 4.4.3 AstraZeneca Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 AstraZeneca Trivalent Inactivated Influenza Vaccine Product Portfolio
  24. 4.4.5 AstraZeneca Recent Developments
  25. 4.5 GlaxoSmithKline
  26. 4.5.1 GlaxoSmithKline Company Information
  27. 4.5.2 GlaxoSmithKline Business Overview
  28. 4.5.3 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product Portfolio
  30. 4.5.5 GlaxoSmithKline Recent Developments
  31. 4.6 Pfizer
  32. 4.6.1 Pfizer Company Information
  33. 4.6.2 Pfizer Business Overview
  34. 4.6.3 Pfizer Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfizer Trivalent Inactivated Influenza Vaccine Product Portfolio
  36. 4.6.5 Pfizer Recent Developments
  37. 4.7 Merck
  38. 4.7.1 Merck Company Information
  39. 4.7.2 Merck Business Overview
  40. 4.7.3 Merck Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Merck Trivalent Inactivated Influenza Vaccine Product Portfolio
  42. 4.7.5 Merck Recent Developments
  43. 4.8 Novartis
  44. 4.8.1 Novartis Company Information
  45. 4.8.2 Novartis Business Overview
  46. 4.8.3 Novartis Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Novartis Trivalent Inactivated Influenza Vaccine Product Portfolio
  48. 4.8.5 Novartis Recent Developments
  49. 4.9 Abbott
  50. 4.9.1 Abbott Company Information
  51. 4.9.2 Abbott Business Overview
  52. 4.9.3 Abbott Trivalent Inactivated Influenza Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Abbott Trivalent Inactivated Influenza Vaccine Product Portfolio
  54. 4.9.5 Abbott Recent Developments
5 Global Trivalent Inactivated Influenza Vaccine Market Scenario by Region
  1. 5.1 Global Trivalent Inactivated Influenza Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Trivalent Inactivated Influenza Vaccine Sales by Region: 2021-2032
  3. 5.2.1 Global Trivalent Inactivated Influenza Vaccine Sales by Region: 2021-2026
  4. 5.2.2 Global Trivalent Inactivated Influenza Vaccine Sales by Region: 2027-2032
  5. 5.3 Global Trivalent Inactivated Influenza Vaccine Revenue by Region: 2021-2032
  6. 5.3.1 Global Trivalent Inactivated Influenza Vaccine Revenue by Region: 2021-2026
  7. 5.3.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Region: 2027-2032
  8. 5.4 North America Trivalent Inactivated Influenza Vaccine Market Facts & Figures by Country
  9. 5.4.1 North America Trivalent Inactivated Influenza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2032)
  11. 5.4.3 North America Trivalent Inactivated Influenza Vaccine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Trivalent Inactivated Influenza Vaccine Market Facts & Figures by Country
  15. 5.5.1 Europe Trivalent Inactivated Influenza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2032)
  17. 5.5.3 Europe Trivalent Inactivated Influenza Vaccine Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Trivalent Inactivated Influenza Vaccine Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Trivalent Inactivated Influenza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Trivalent Inactivated Influenza Vaccine Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Trivalent Inactivated Influenza Vaccine Market Facts & Figures by Country
  35. 5.7.1 South America Trivalent Inactivated Influenza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2032)
  37. 5.7.3 South America Trivalent Inactivated Influenza Vaccine Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Trivalent Inactivated Influenza Vaccine Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Trivalent Inactivated Influenza Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Trivalent Inactivated Influenza Vaccine Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Trivalent Inactivated Influenza Vaccine Sales by Type (2021-2032)
  2. 6.1.1 Global Trivalent Inactivated Influenza Vaccine Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2021-2032)
  5. 6.2.1 Global Trivalent Inactivated Influenza Vaccine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Trivalent Inactivated Influenza Vaccine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Trivalent Inactivated Influenza Vaccine Sales by Application (2021-2032)
  2. 7.1.1 Global Trivalent Inactivated Influenza Vaccine Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2021-2032)
  5. 7.2.1 Global Trivalent Inactivated Influenza Vaccine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Trivalent Inactivated Influenza Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Trivalent Inactivated Influenza Vaccine Value Chain Analysis
  2. 8.1.1 Trivalent Inactivated Influenza Vaccine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Trivalent Inactivated Influenza Vaccine Production Mode & Process
  5. 8.2 Trivalent Inactivated Influenza Vaccine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Trivalent Inactivated Influenza Vaccine Distributors
  8. 8.2.3 Trivalent Inactivated Influenza Vaccine Customers
9 Global Trivalent Inactivated Influenza Vaccine Analyzing Market Dynamics
  1. 9.1 Trivalent Inactivated Influenza Vaccine Industry Trends
  2. 9.2 Trivalent Inactivated Influenza Vaccine Industry Drivers
  3. 9.3 Trivalent Inactivated Influenza Vaccine Industry Opportunities and Challenges
  4. 9.4 Trivalent Inactivated Influenza Vaccine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst